AIDS Groups Express Concern About Potential for New HIV Med Advertising to 'Scare Off' Patients The Wall Street Journal on Monday examined a new trend for drugmakers marketing HIV/AIDS treatments to release ads that 'tak[e] aim at rival HIV drugs, hinting at side effects and other drawbacks.' Drug companies have 'traditionally sold'...
New Antiretroviral Advertising May Scare Off Patients The Wall Street Journal on Monday examined a new trend for drugmakers marketing HIV/AIDS treatments to release ads that 'tak[e] aim at rival HIV drugs, hinting at side effects and other drawbacks.' Drug companies have 'traditionally sold'...
Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year A new 100 mg tablet formulation of the protease inhibitor ritonavir (Norvir) appears to be equivalent to the current soft-gel capsule formulation in terms of side-effects and boosting potential, according to data presented to the XVII...
Lopinavir/ritonavir may curb lipoatrophy in HIV NEW YORK (Reuters Health) - Limb fat loss is less frequent in patients with HIV who receive lopinavir/ritonavir (Kaletra) therapy compared to efavirenz plus zidovudine/lamivudine, according to North American and Spanish researchers.
Similarity in Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FT Reported by Jules Levin IAC, Aug 3-8, 2008, Mexico City From Jules: As you know by know there was controversy and much discussion at this conference over that ACTG 5202 found a higher rate of virological failures in patients with >100,000...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Normal Version MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily...
Drug companies increase cost of medications at a faster rate Prices of 64 drugs are expected to more than double before year's end THE ASSOCIATED PRESS WASHINGTON Pharmaceutical companies are increasingly raising the prices of specialty medications by 100 percent or more -- sometimes much more --...
Drug companies increase cost of medications at a faster rate Prices of 64 drugs are expected to more than double before year's end THE ASSOCIATED PRESS WASHINGTON Pharmaceutical companies are increasingly raising the prices of specialty medications by 100 percent or more -- sometimes much more --...
Abbott Study Shows Investigational Heat-Stable Norvir(R) Tablet Provides Similar Drug Levels to Current Norvir Pivotal Study of Norvir Tablet Bioavailability Will Form the Basis of Request for Priority Regulatory Review MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- Abbott presented pivotal data at the XVII International AIDS Conference (AIDS 2008)...
Efficacy and Safety By Racial Group in ARV-Naive Subjects Treated With Atazanavir/Ritonavir or Lopinavir/Riton Ola Reported by Jules Levin IAS, Mexico City, Aug 3-8, 2008 from JulesBlacks Have Better Lipids Responses Than Whites to Both Reyataz and Kaletra AUTHOR CONCLUSIONS Both once-daily ATV/RTV and twice-daily LPV/RTV regimens demonstrated...
Abbott says investigational Norvir tablet showed bioavailability similar to soft-gelatin capsule in HIV treatm (RTTNews) - Health care company Abbott Laboratories (ABT: News, Chart, Quote ) said on Thursday that pivotal data of investigational tablet Norvir, or ritonavir, which was presented at the XVII International AIDS Conference in Mexico City,...
Head-to-Head 96-Week Study Shows Epizcom is Comparable to Truvada in Efficacy and Safety Measures in HIV Treat /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) (tenofovir DF + emtricitabine) as a...
Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race a 2:20 PM EDT MEXICO CITY, Aug.5 -- Initial treatment regimens containing once-daily or twice-daily dosing of Abbott's (NYSE: ABT) protease inhibitor Kaletra(R) (lopinavir/ritonavir) tablet provided similar results for controlling the virus...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV EXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK - News) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV MEXICO CITY, Aug.7 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced that 96-week data from the HEAT study show that once-daily EPZICOM (abacavir + lamivudine) provides comparable efficacy to once-daily Truvada(R) ...
